None of the 29 investors followed here reported a position in RNAZ in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a RNAZ trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 2, 2026 | Defj, LlcBeneficial Owner of more than 10% of a Class of Security | — | 13.83M | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 38.9 | 1.3 | -10.4 | -7.0 | -35.8 | 20.8 | -26.6 | -53.9 | -20.0 | 0.0 | −75.4% | ||
| 2025 | 124.3 | -73.8 | -75.0 | -17.8 | -40.4 | 14.9 | 42.3 | -12.3 | 10.5 | 4.2 | -17.1 | -26.5 | −92.8% |
| 2024 | -89.5 | 2.0 | -3.1 | -11.1 | 192.4 | -43.4 | -72.1 | -6.1 | 117.1 | -18.6 | -25.2 | -70.7 | −98.5% |
| 2023 | 11.6 | -30.6 | -34.9 | -6.8 | -33.5 | -45.2 | -4.3 | -34.1 | -65.3 | -26.4 | -33.5 | -32.9 | −98.8% |
| 2022 | -9.4 | -7.4 | 35.2 | -5.2 | -32.6 | -31.5 | 12.7 | -15.5 | -8.3 | -38.9 | -40.5 | 68.2 | −73.5% |
| 2021 | 4.5 | -1.6 | -5.4 | -2.8 | -7.6 | −12.7% |
No analyst coverage for this instrument.
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor. The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.